PE-041 Impact associated with pertuzumab and trastuzumab SC and IV formulations utilization in metastatic HER2- positive breast cancer patients treated in SUS
Introduction: Current gold standard therapy for metastatic breast cancer (mBC) HER2-positive patients – double blockage with pertuzumab and trastuzumab (P+T) – is available in the Sistema Único de Saúde (SUS) as intravenous (IV) formulations. Despite important clinical and economic benefits that th...
Saved in:
| Main Authors: | Isabel Monteiro, Florine Cordeiro, Tamie Martins, Clarissa Medeiros |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Instituto Nacional de Assistência Farmacêutica e Farmacoeconomia
2025-03-01
|
| Series: | Jornal de Assistência Farmacêutica e Farmacoeconomia |
| Subjects: | |
| Online Access: | https://www.ojs.jaff.org.br/ojs/index.php/jaff/article/view/1152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of different formulations of tocilizumab in the treatment of patients with moderate to severe COVID-19
by: E. I. Veselova, et al.
Published: (2021-02-01) -
Analysis of trastuzumab therapy’s efficacy with or without pertuzumab combination in the metastatic HER2-positive breast cancer an oncology hospital of Pernambuco
by: Kaline Nascimento dos Santos Lima, et al.
Published: (2022-10-01) -
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC
by: Federico Cappuzzo, MD, et al.
Published: (2025-05-01) -
Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections
by: Miguel Figallo, et al.
Published: (2024-01-01) -
Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates
by: Victoria Koch, et al.
Published: (2025-12-01)